{
    "id": 28898,
    "fullName": "BRAF L514V",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "BRAF L514V lies within the protein kinase domain of the Braf protein (UniProt.org). L514V is predicted to lead to a gain of Braf function as indicated by moderate increase of Mek and Erk phosphorylation in culture, enhanced dimerization when expressed in cis with BRAF V600E, and is associated with resistance to Raf inhibitors (PMID: 29880583).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 673,
        "geneSymbol": "BRAF",
        "terms": [
            "BRAF",
            "B-raf",
            "B-RAF1",
            "BRAF1",
            "NS7",
            "RAFB1"
        ]
    },
    "variant": "L514V",
    "createDate": "11/08/2018",
    "updateDate": "12/28/2018",
    "referenceTranscriptCoordinates": {
        "id": 177574,
        "transcript": "NM_004333",
        "gDna": "chr7:g.140777066G>C",
        "cDna": "c.1540C>G",
        "protein": "p.L514V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15621,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) did not inhibit Erk and Mek signaling in breast cancer cells expressing BRAF L514V in culture (PMID: 29880583).",
            "molecularProfile": {
                "id": 30812,
                "profileName": "BRAF L514V"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15194,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SCH772984 resulted in similar inhibition of Erk phosphorylation and colony formation in melanoma cells expressing BRAF L514V in cis with V600E and cells expressing BRAF V600E alone in culture (PMID: 29880583).",
            "molecularProfile": {
                "id": 30813,
                "profileName": "BRAF L514V BRAF V600E"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15192,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB3245 resulted in similar inhibition of Erk phosphorylation and colony formation in melanoma cells expressing BRAF L514V in cis with V600E and cells expressing BRAF V600E alone in culture (PMID: 29880583).",
            "molecularProfile": {
                "id": 30813,
                "profileName": "BRAF L514V BRAF V600E"
            },
            "therapy": {
                "id": 7465,
                "therapyName": "BGB3245",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15193,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB3290 resulted in similar inhibition of Erk phosphorylation and colony formation in melanoma cells expressing BRAF L514V in cis with V600E and cells expressing BRAF V600E alone in culture (PMID: 29880583).",
            "molecularProfile": {
                "id": 30813,
                "profileName": "BRAF L514V BRAF V600E"
            },
            "therapy": {
                "id": 7464,
                "therapyName": "BGB3290",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15190,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells expressing BRAF L514V in cis with V600E demonstrated decreased response to PLX8394-induced inhibition of Erk phosphorylation and colony formation compared to cells expressing BRAF V600E in culture (PMID: 29880583).",
            "molecularProfile": {
                "id": 30813,
                "profileName": "BRAF L514V BRAF V600E"
            },
            "therapy": {
                "id": 1041,
                "therapyName": "PLX8394",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15191,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells expressing BRAF L514V in cis with V600E demonstrated decreased response to TAK-632-induced inhibition of Erk phosphorylation and colony formation compared to cells expressing BRAF V600E in culture (PMID: 29880583).",
            "molecularProfile": {
                "id": 30813,
                "profileName": "BRAF L514V BRAF V600E"
            },
            "therapy": {
                "id": 3300,
                "therapyName": "TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15195,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells expressing BRAF L514V in cis with V600E demonstrated decreased response to Mekinist (trametinib)-induced inhibition of Erk phosphorylation and colony formation compared to cells expressing BRAF V600E in culture (PMID: 29880583).",
            "molecularProfile": {
                "id": 30813,
                "profileName": "BRAF L514V BRAF V600E"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15189,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells expressing BRAF L514V in cis with V600E demonstrated decreased response to Tafinlar (dabrafenib)-induced inhibition of Erk phosphorylation and colony formation compared to cells expressing BRAF V600E in culture (PMID: 29880583).",
            "molecularProfile": {
                "id": 30813,
                "profileName": "BRAF L514V BRAF V600E"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15188,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells expressing BRAF L514V in cis with V600E demonstrated decreased response to Zelboraf (vemurafenib)-induced inhibition of Erk phosphorylation and colony formation compared to cells expressing BRAF V600E in culture (PMID: 29880583).",
            "molecularProfile": {
                "id": 30813,
                "profileName": "BRAF L514V BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15175,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a pediatric patient with anaplastic ganglioglioma harboring BRAF V600E progressed after initial response to Tafinlar (dabrafenib) treatment, and was found to have acquired a BRAF L514V in cis with BRAF V600E, which conferred dabrafenib resistance in culture (PMID: 29880583).",
            "molecularProfile": {
                "id": 30813,
                "profileName": "BRAF L514V BRAF V600E"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 5078,
                "name": "ganglioglioma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 30812,
            "profileName": "BRAF L514V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30813,
            "profileName": "BRAF L514V BRAF V600E",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 177574,
            "transcript": "NM_004333",
            "gDna": "chr7:g.140777066G>C",
            "cDna": "c.1540C>G",
            "protein": "p.L514V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 177573,
            "transcript": "XM_005250045",
            "gDna": "chr7:g.140777066G>C",
            "cDna": "c.1540C>G",
            "protein": "p.L514V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}